Hudson Bay Capital Management LP Hutchmed (China) LTD Transaction History

Hudson Bay Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.59 - $20.77 $3.76 Million - $9.09 Million	-437,636 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$15.52 - $35.65 $698,400 - $1.6 Million	45,000 Added 11.46%	437,636 $8.28 Million
Q1 2021 May 14, 2021	SELL	$27.01 - $36.8 $3.32 Million - $4.53 Million	-122,970 Reduced 23.85%	392,636 $11.1 Million
Q1 2020 May 14, 2020	BUY	$15.19 - $29.51 $2.86 Million - $5.55 Million	188,008 Added 57.39%	515,606 $9.2 Million
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $6.6 Million - $9.53 Million	300,000 Added 1087.04%	327,598 $7.21 Million
Q1 2019 May 15, 2019	BUY	$21.27 - $30.58 $106,350 - $152,900	5,000 Added 22.13%	27,598 $844,000
Q4 2018 Feb 13, 2019	BUY	$23.09 - $37.69 $124,639 - $203,450	5,398 Added 31.38%	22,598 $522,000
Q3 2017 Nov 13, 2017	BUY	$22.15 - $27.5 $380,980 - $473,000	17,200	17,200 $469,000

6.96M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.34B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.